230510 Eblasakimab improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study (ISID)

230510 Eblasakimab improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study (ISID)